To advance Systemic lupus erythematosus (SLE) research, GemPharmatech has developed a humanized SLE mouse model by transferring PBMCs from SLE patients into immunodeficient mice (NCG mice). This model replicates key disease features, including high levels of human auto-antibodies and renal immune complex deposition. Furthermore, this model responds to B-cell targeted therapeutic antibodies, demonstrating its utility in evaluating novel therapeutic modalities.